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clinical research/practice, editorial/personal viewpoint, infection and infectious agents-viral: hepatitis C, infectious disease, liver disease: infectious, liver transplantation/hepatology for all LT patients in an era of donor shortage. Importantly, clinical follow-up data are currently restricted to relatively short-term outcomes and thus the natural history after successful DAA therapy and its impact on LT requirement and overall longer-term utility is as yet undelineated. It is possible that some advanced "high Model for End-Stage Liver Disease (MELD)" patients are beyond therapy and may not gain significant benefit from HCV eradication. Overall, despite pressures on the donor pool and restricted LT access, the primacy of LT over antiviral therapy still exists in a DAA environment. Assessing clinical trial data but, more pertinently, reviewing real-life clinical experience and outcomes (both virologic and clinical) provides insight into the impact of DAAs at various points of the LT pathway.
| DA A THER APY AND HEPATO CELLUL AR C ARCINOMA IN THE LT S E T TING
The impact of DAA therapy on the development and/or recurrence of hepatocellular carcinoma (HCC) in HCV patients is controversial, 12 and this controversy extends into the LT setting. 13 compared with the IFN era 14 ; however, further analyses demonstrated that these results likely reflected differences in treated patient populations. 15, 16 HCC recurrence post-DAAs has proved more controversial, with studies suggesting that not only was the incidence of HCC recurrence higher, but also recurrent tumors were more aggressive post-DAAs. 15, 17 Furthermore, recent data suggest an impact of the timing of DAA therapy with a higher rate of HCC recurrence reported in patients treated with DAAs ≤6 months after achieving a complete response to HCC compared with those treated >6 months.
18
A recent study focused on patients waitlisted for LT, using a contemporaneous untreated control group to better assess the benefits vs harms of DAA therapy. 19 No association was observed between DAA use and increased risk of HCC recurrence after complete response to LRT. Moreover, the authors showed that DAA treatment was associated with reduced waitlist dropout due to tumor progression or death, and that DAA use was not associated with decreased probability of LT or overall survival. Finally, results from a recent study suggested that DAAs are less effective in patients with concomitant HCC than in cirrhotic patients without HCC. 20 This study included 17 487 HCV patients treated with DAAs, and the authors reported lower SVR rates in the group with HCC than in those without (74% and 91%, respectively). On multivariate analysis, HCC was associated with a 62% lower likelihood of SVR (P < .001). A second study found patients with HCC almost eight times more likely to fail DAA therapy than those without (21% and 12%, respectively; P = .009). 21 
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| TR AN S PL ANT OF H C V-P OS ITIVE ORG ANS
Our main focus in this review is the management options available to patients requiring LT; however, the ability to cure HCV has the potential for an even more widespread impact on the transplant setting by optimizing the allocation of other donor organs.
Reese et al 22 taking place related to LT. 23 Indeed, the prevalence of anti-HCV positivity in organ donors is generally higher than that reported in the general population, albeit with geographic differences. 24 Transmission to the recipient is typical in active replication cases, a situation which until recently was present in about half of anti-HCV-positive donors but is expected to significantly decrease in the future as general population patients are treated effectively with DAAs. 25 In the IFN era, these grafts were occasionally used but not homogeneously increased. 26 For a while, prior to availability of highly effective pangenotypic regimens, the possibility of recipients acquiring the donor HCV genotype was a concern in relation to genotype (GT) 1/GT 3 recipient-donor mismatching.
Interestingly, a recent study using the United Network for Organ 
| PRE-LT ANTIVIR AL THER APY
The rationale for pre-LT DAA therapy is to prevent HCV infection The clinical evidence on the efficacy and safety of DAAs in the pretransplant setting is summarized in Supplementary Table S1 .
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Studies show that combination DAA regimens are well tolerated, especially compared with historic standard of care, allowing most patients to undergo antiviral therapy without a significant additive toxicity. Data also infer an improvement in MELD score in a significant proportion of HCV patients post-DAA therapy. If antiviral therapy results in viral eradication with concomitant MELD score reduction, and hepatic function can be well maintained, conceptually, some patients could be delisted. 24, 25 However, it remains unclear how many patients with advanced liver failure and high MELD scores can be "rescued," potentially avoiding LT altogether.
A large European study 33 found that 20% (21/103) of patients with decompensated cirrhosis could be delisted due to clinical improvement after a 60-week median period. The probability of being delisted was high in patients with a MELD score <16 (~35%) but minimal in those with a MELD score >20 (~5%). of ledipasvir/sofosbuvir with ribavirin) in pre-LT Child-TurcottePugh (CTP) B/C patients. 35, 36 There are, however, two major issues in applying these data to real-life practice. Firstly, data are lacking in severely ill patients (MELD score >20). Secondly, as sofosbuvir-based regimens are not licensed for patients with a glomerular filtration rate <30 mL/min/1.73 m 2 , MELD scores in patients from these studies were driven by bilirubin and the international normalized ratio and thus these patients may not be representative of real-world comorbidity profiles. These and other unanswered questions in achieving best practice are considered in Table 1 .
37,38
TA B L E 1 Clinical issues that remain to be addressed in the pre-LT population Q. Who are the best candidates for DAA-based pre-LT therapy?
A: All patients should be considered for treatment with DAAs; however, insufficient data exist on their role in the most seriously ill patients (most studies excluded patients with MELD >20), including those with renal impairment.
Q. What criteria should influence the decision to treat?
A: Expected time on the LT waiting list, expected clinical benefit, presence of concomitant HCC, together with renal and hepatic function, allied to the probability of achieving SVR, which is lower in CTP C patients.
Q.
What is the optimal timing for starting treatment when the date of LT is unknown?
A: Ideally patients should receive a full course of therapy. However, in patients with lower chances of achieving an SVR and obtaining a sufficient clinical benefit such as to avoid LT (eg CTP C patients), efforts should be made to commence treatment such that therapy is maintained up to the time of LT.
Q. Should DAA-based therapy be continued after LT when the patient has been transplanted after too short a duration of treatment?
A: A priori there are no formal contraindications to continue therapy post-LT. However, given the severely ill status of patients currently undergoing LT in most centers and the potential for clinically significant post-LT complications, such as renal failure and hemorrhage among others, it is unlikely that patients will be able to receive continuous antiviral therapy in the immediate posttransplant setting.
Q. Might it be advisable to delay LT in favor of a longer course of DAA-based therapy?
A: The timing of transplant is relatively fixed whereas timing of antiviral therapy can be flexible, and thus it can be argued not, given the pressure on the donor organ pool.
Q.
How should listed patients be managed with improved liver function post-DAA therapy (and hence with reduced MELD scores) but who continue to need LT due to complications from portal hypertension, such as ascites and hepatic encephalopathy?
A: Unless MELD exception points are given to these patients, they drop down the LT waiting list and may never be transplanted, a situation which has been termed "MELD purgatory."
Q. Can we consider delisting patients in whom there is significant improvement in liver function? What about delisting patients with compensated cirrhosis and small HCC who achieve SVR together with a complete tumor remission to ablation therapies?
A: Patients with MELD reduction to a score of <14 together with complete clinical "recompensation" can be delisted from the transplant waiting list. The long-term outcome of these patients is still not completely understood.
In turn, the management of those with a small HCC (<2-3 cm) who clear the virus and respond completely to ablation therapy is still under debate. Indeed, dropout from the LT waiting list has been shown to occur in only a minority of patients (1-and 2-y probabilities of dropout of 1.3% and 1.6%, respectively, for patients with small HCC tumors fulfilling specific criteria [1 tumor of 2-3 cm, a complete response after the first LRT and an AFP level ≤20 ng/mL after the first LRT]). 37 This proportion rises significantly in those patients not fulfilling these criteria; therefore, while the former group can be delisted (or rather inactivated), patients in the latter group should remain on the waiting list for LT regardless of antiviral response to new DAAs. Whether oral antiviral therapy may modify these outcomes is still under evaluation.
Q. How should we monitor patients while on treatment for prevention of HCV recurrence?
A: Monitoring of waitlisted patients is highly dependent on expected time to LT and severity of liver disease. In those with high MELD scores, and short expected time to transplantation, and given the association between duration of viral undetectability and prevention of HCV recurrence, HCV RNA should be tested every 2 weeks until viral negativity and then monthly up to EOT (or LT if it occurs beforehand). Assessment of SVR4, 12, and 24 should then be performed in these patients. In the remainder, monitoring similar to that performed in chronic HCV patients is advised.
Q. Do we have any evidence to suggest that a pretransplant (prophylactic) strategy impacts survival? Importantly, real-world data have mostly confirmed clinical trial data, including (a) the decrease in MELD scores in most patients;
(b) the reduction in liver-related complications, particularly in those without severely affected liver function 39 ; and (c) the safety limitations in patients treated at advanced stages of liver disease. 40 
| PERI -LT TRE ATMENT
Peri-LT treatment represents a potential alternative to pre-LT therapy. Early post-LT (preemptive) treatment is designed to eliminate the risk of HCV recurrence in the immediate post-LT period (2-8 weeks). 41 Peri-LT treatment takes place while patients are recovering from surgery, receiving high-dose immunosuppression and other concomitantly administered drugs, when the risk of acute rejection is greatest 42 and when most complications (including renal failure, neurotoxicity, or severe infections) occur.
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Evidence for the use of DAAs in the peri-LT setting is scarce.
43-45
Available data together with the efficacy and safety profiles of DAAs and a low propensity to interact with immunosuppressive medications suggest that this is a viable approach, especially since HCV viral load can increase within hours of transplantation in some patients. 1 In a recent study of preemptive therapy in 37 HCV-positive patients undergoing LT, 4 weeks' perioperative ledipasvir/sofosbuvir led to a high SVR rate. 45 The only patient with virologic relapse had NS5A resistance at baseline and a response to an additional 12 weeks' therapy, TA B L E 2 Clinical issues that remain to be addressed in the post-LT population Q. When should patients be targeted for post-LT therapy with DAAs?
A: Given their excellent safety and tolerability profiles, early initiation of therapy after LT to avoid posttransplant management problems that are sometimes difficult to differentiate from recurrent HCV.
Q. Should patients be treated preemptively post-LT?
A: Preemptive therapy may not be ideal immediately following transplant given the high likelihood of complications. There is a paucity of data in this cohort. Early antiviral therapy post-LT should be reserved for those with aggressive recurrence in danger of graft loss and death and for patients receiving anti-HCV+ NAT+ organs.
Q. Would patients who failed prior therapy pre-LT be contraindicated for post-LT therapy?
A: There are no obvious theoretical objections to re-treating patients. Evidence to suggest that DAAs can be used as rescue therapy is reported (see supplementary tables). 35, 36 Viral sequencing might be useful to determine the best combination therapy.
Q. What do we know about rates of relapse post-LT and how should relapsed patients be managed?
A: There are limited data available, but in theory the same approach used for non-LT patients could be applied to LT patients.
Q. What is the best strategy for patients diagnosed with fibrosing cholestatic hepatitis?
A: Emergency treatment is needed. Studies of DAA combination therapy without IFN show normalization of bilirubin and clinical improvement in the majority of patients in association with SVR (see supplementary tables). 35, 36 Dramatic improvement in survival is expected, while histologic outcome after SVR is awaited.
Q. To what extent are HCV, graft function, and renal function linked?
A: There is a causal link between HCV infection and kidney disease, 48 although renal impairment is often multifactorial. Renal insufficiency is also a frequent occurrence following liver transplantation; more than 75% of transplanted patients have serum creatinine >1.6 mg/dL within 3 y of transplantation. 49 Patients with renal impairment constitute an important population among those awaiting LT.
48
Q. How should patients with severely impaired renal function (eGFR <30 mL/min/1.73 m 2 ) be managed?
A: There is evidence to suggest that licensed DAAs can be used with success in patients with renal dysfunction, although data on patients with severe impairment (eGFR <30 mL/min/1.73 m 2 ) are limited to date. [49] [50] [51] [52] Treatment of primarily noncirrhotic GT 1 patients with chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ) with ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin or elbasvir/grazoprevir for 12 weeks was shown to be effective and well tolerated with SVR rates of 90% and 94%, respectively. 50, 51 More recently, glecaprevir/pibrentasvir was shown to be effective and well tolerated in primarily noncirrhotic GT 1-6 patients with chronic kidney disease with an overall SVR rate of 98%. Potential candidates for perioperative therapy include patients in whom pre-LT antiviral therapy is deemed insufficient (virus undetectable for <1 month). Table S2 ). AE frequency was similar to that in the pre-LT setting with fatigue, anemia, headache, and nausea among the most common. The AE profile improved when ribavirin was excluded. Except for the treatment regimen used in CORAL-1, 47 significant interactions with immunosuppressive agents were not reported. Acute rejection was rare across all studies and deaths occurred primarily during "compassionate use" programs (Supplementary Table S2 ).
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The objective of posttransplant therapy is to treat recurrent HCV and prolong life. Good tolerability and efficacy outcomes mandate the utilization of earlier post-LT DAA therapy before significant graft and extrahepatic manifestations of HCV become clinically apparent.
In patients with significant post-LT HCV recurrence and decompensated cirrhosis, DAAs are less efficacious and more hazardous, emphasizing the requirement for earlier antiviral therapy. As discussed for pre-LT therapy, improvements in liver function are also observed in post-LT decompensated CTP B and CTP C patients.
The clinical benefits of DAAs in cirrhotic and advanced liver disease LT patients have been described. However, despite the substantial and growing evidence on the use of DAAs in the posttransplant setting, questions remain (Table 2) . Bristol-Myers Squibb, Gilead Sciences, Roche. Advisory Boards:
